Royal Bank Of Canada Kala Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.25 - $0.36 $87 - $125	348 Added 27.86%	1,597 $0
Q2 2022 Aug 15, 2022	SELL	$0.3 - $1.31 $831 - $3,631	-2,772 Reduced 68.94%	1,249 $0
Q1 2022 May 16, 2022	SELL	$0.61 - $1.84 $4,318 - $13,027	-7,080 Reduced 63.78%	4,021 $5,000
Q4 2021 Feb 14, 2022	BUY	$1.16 - $2.74 $5,469 - $12,919	4,715 Added 73.83%	11,101 $14,000
Q3 2021 Nov 15, 2021	BUY	$2.62 - $5.43 $4,949 - $10,257	1,889 Added 42.01%	6,386 $17,000

Q2 2021 Aug 16, 2021	BUY	$5.06 - $8.15 $22,754 - $36,650	4,497 New	4,497 $25,000

Ticker KALA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,464,160
Market Cap $10.4M
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.